Habib J. Dable - 05 Feb 2026 Form 4 Insider Report for SpyGlass Pharma, Inc. (SGP)

Reporting relationship: Director
Issuer ticker: SGP
Reported as of: 05 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2026, 16:49:04 UTC
Prior SEC filing: 07 Nov 2025
Next SEC filing: 20 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Brian Aukshunas, as Attorney-in-Fact

Key filing fact

Habib J. Dable filed Form 4 for SpyGlass Pharma, Inc. (SGP) on 09 Feb 2026.

Key facts

This page summarizes Habib J. Dable's Form 4 filing for SpyGlass Pharma, Inc. (SGP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Feb 2026, 16:49.

Change

Previous filing in this sequence was filed on 07 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001690773 Primary reporting owner

Dable Habib J

Relationship: Director
Address: C/O SPYGLASS PHARMA, INC., 27061 ALISO CREEK RD., SUITE 100, ALISO VIEJO
Signature: /s/ Brian Aukshunas, as Attorney-in-Fact
Signature date: 09 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +27,400
Change %
Price: $0.000000
Shares after: 27,400
Date: 05 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,400
Exercise price: $16.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable vesting date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Date of Grant on the same day of the month as the Date of Grant (and if there is no corresponding day, on the last day of the month). "Date of Grant" shall mean February 5, 2026.